The genes encoding cytokines IL-2, IL-10 and IL-12B are primary 1α,25(OH)2D3 target genes

Matilainen, Juha M.; Räsänen, Antti; Gynther, Petra; Vaïsänen, Sami

doi:10.1016/j.jsbmb.2010.03.020

Cited by 46 publications

(33 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with MS, 25(OH)D, but not 1a,25(OH) 2 D, levels correlate with the ability of Treg cells to suppress the proliferation of activated T responder cells and inversely correlated with Th1/Th2 ratio [123]. IL-2, IL-10, and IL-12 genes in T cells have regions which bind to VDR and 1a,25(OH) 2 D may directly play a role in the transcription of these cytokines in T cells [124]. The ability of 1a,25(OH) 2 D to modulate the adaptive immune system may explain the association of vitamin D supplementation and higher 25(OH)D levels with a lower risk of multiple autoimmune diseases.…”

Section: Adaptive Immunitymentioning

confidence: 97%

D-livering the message: The importance of vitamin D status in chronic liver disease

Kitson

Roberts

2012

Journal of Hepatology

202

171

View full text Add to dashboard Cite

Vitamin D is synthesized predominantly in the liver and functions as an important secosteroid hormone with pleiotropic effects. While its key regulatory role in calcium and bone homeostasis is well established, recently there is increasing recognition that vitamin D also regulates cell proliferation and differentiation, and has immunomodulatory, anti-inflammatory and anti-fibrotic properties. These non-skeletal effects are relevant in the pathogenesis and treatment of many causes of chronic liver disease. Vitamin D deficiency is frequently present in chronic liver disease and may predict non-response to antiviral therapy in chronic hepatitis C. Small studies suggest that vitamin D supplementation improves sustained viral response rates, while 1α-hydroxylase polymorphisms and vitamin D-binding protein are also implicated in therapeutic outcomes. Vitamin D deficiency also closely relates to the severity of non-alcoholic fatty liver disease (NAFLD) and is implicated in the pathogenesis of insulin resistance, a key factor in the development of NAFLD. In preclinical studies, phototherapy and vitamin D supplementation ameliorate NAFLD histopathology, while vitamin D is a powerful anti-fibrotic against thioacetamide liver injury. In liver transplant recipients severe vitamin D deficiency predicts, and vitamin D supplementation prevents, acute cellular rejection. The role of vitamin D in the activation and regulation of both innate and adaptive immune systems may explain its importance in the above liver diseases. Further prospective studies are therefore warranted to investigate the therapeutic impact of vitamin D supplementation in chronic liver disease.

show abstract

Section: Adaptive Immunitymentioning

confidence: 97%

D-livering the message: The importance of vitamin D status in chronic liver disease

Kitson

Roberts

2012

Journal of Hepatology

202

171

View full text Add to dashboard Cite

show abstract

“…For example, limited data from mechanistic studies suggest that, in contrast to the inflammatory markers described above, both IL10 and IL12 reduce colorectal cancer progression (58,59). At the same time, calcitriol seems to decrease levels of these cytokines (60,61). Together, this may represent a mechanism by which calcitriol might promote tumor progression.…”

Section: Tgfb1mentioning

confidence: 99%

Vitamin D, Inflammation, and Colorectal Cancer Progression: A Review of Mechanistic Studies and Future Directions for Epidemiological Studies

Harten-Gerritsen

Balvers

Witkamp

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Survival from colorectal cancer is positively associated with vitamin D status. However, whether this association is causal remains unclear. Inflammatory processes may link vitamin D to colorectal cancer survival, and therefore investigating inflammatory markers as potential mediators may be a valuable next step. This review starts with an overview of inflammatory processes suggested to be involved in colorectal cancer progression and regulated by vitamin D. Next, we provide recommendations on how to study inflammatory markers in future epidemiologic studies on vitamin D and colorectal cancer survival. Mechanistic studies have shown that calcitriol-active form of vitamin Dinfluences inflammatory processes involved in cancer progression, including the enzyme cyclooxygenase 2, the NF-kB pathway, and the expression of the cytokines TNFa, IL1b, IL6, IL8, IL17, and TGFb1. Based on this and taking into account methodologic issues, we recommend to include analysis of specific soluble peptides and proteins, such as cytokines, in future epidemiologic studies on this issue. Vitamin D and the markers should preferably be measured at multiple time points during disease progression or recovery and analyzed using mediation analysis. Including these markers in epidemiologic studies may help answer whether inflammation mediates a causal relationship between vitamin D and colorectal cancer survival. Cancer Epidemiol Biomarkers Prev; 24(12); 1820-8. Ó2015 AACR.

show abstract

“…It has complex effects in modulating the immune response in MS, mainly by decreasing the proinflammatory lymphocytes [2,11]. It regulates the transcription of IL-10 gene [13]. It has been reported that it inhibits the proliferation of cells that release inflammatory cytokines and increases IL-10 production and secretion [3,14].…”

Section: Introductionmentioning

confidence: 99%

Short-Term Effect of High-Dose Vitamin D on the Level of Interleukin 10 in Patients with Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Ashtari¹,

Toghianifar²,

Zarkesh-Esfahani

et al. 2015

Neuroimmunomodulation

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. Vitamin D has been related to the prevention of MS and to modulating its course. Recent studies have shown the safety of high-dose vitamin D in MS. Objective: This study compared the effects of high-dose vitamin D on interleukin 10 (IL-10) levels in MS patients in a double-blind, randomized clinical trial. Methods: Ninety-four patients with relapsing remitting MS (RRMS) were randomized into a treatment and a placebo group. Both groups received conventional MS treatment. The intervention group received 50,000 IU of vitamin D every 5 days for 3 months. IL-10 was measured at baseline and after 3 months. Results: Serum levels of IL-10 were (median ± IQR): 12.58 ± 11.97 and 10.97 ± 9.97 pg/ml in the intervention and placebo groups, respectively, at baseline (p = 0.161); after 3 months, these levels were 13.76 ± 18.95 and 11.31 ± 19.63 pg/ml, respectively (p = 0.158). The IL-10 level increased significantly after receiving high-dose vitamin D for 3 months (β = 0.737, p = 0.015 and R² = 0.91). Conclusion: IL-10 levels increased significantly in RRMS patients after taking high-dose vitamin D₃ for 3 months. High-dose vitamin D might be useful in promoting an anti-inflammatory state in RRMS patients.

show abstract

The genes encoding cytokines IL-2, IL-10 and IL-12B are primary 1α,25(OH)2D3 target genes

Cited by 46 publications

References 17 publications

D-livering the message: The importance of vitamin D status in chronic liver disease

D-livering the message: The importance of vitamin D status in chronic liver disease

Vitamin D, Inflammation, and Colorectal Cancer Progression: A Review of Mechanistic Studies and Future Directions for Epidemiological Studies

Short-Term Effect of High-Dose Vitamin D on the Level of Interleukin 10 in Patients with Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Contact Info

Product

Resources

About